{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:14:08Z","timestamp":1793330048338,"version":"4.5.0"},"reference-count":4,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaad.2026.02.042","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:02:24Z","timestamp":1771315344000},"page":"1826-1827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3699-875X","authenticated-orcid":false,"given":"Henry O.","family":"Herrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Bordeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2026.02.042_bib1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaad.2024.03.021","article-title":"Dermatologic findings associated with semaglutide use: a scoping review","volume":"91","author":"Tran","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.02.042_bib2","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/ijd.17246","article-title":"GLP-1 agonists and hair loss: a call for further investigation","volume":"63","author":"Desai","year":"2024","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.02.042_bib3","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","article-title":"Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study","volume":"92","author":"Burke","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.02.042_bib4","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1111\/jdv.20197","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023","volume":"39","author":"Godfrey","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226002483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226002483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:04:27Z","timestamp":1779192267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226002483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":4,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0190962226002483"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.02.042","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.02.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}